• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Medtronic touts Endurant stent graft data

Medtronic touts Endurant stent graft data

April 18, 2014 By Brad Perriello

Medtronic touts Endurant stent graft data

Medtronic (NYSE:MDT) said data from a pair of clinical trials evaluating its Endurant stent graft for abdominal aortic aneurysms "affirm the Endurant stent graft’s durable, consistent and proven outcomes."

The data, from the independent Pandora study and the Medtronic-sponsored Engage trial, showed low rates of "aneurysm-related" mortality, reintervention, stent graft migration and conversion to open surgery, according to a press release.

The 273-patient Pandora trial, an "all-comers" study, met its primary endpoint of reintervention in 9.5% of cases over a median period of more than 3½ years, according to the release. Secondary endpoints for proximal migration (0%), Type I/III endoleaks (2%) and AAA-related death (0.3%) were also met, Medtronic said.

"The findings of this independently executed study are consistent with those published from Engage, the largest contemporary postmarket study on a single stent graft," Dr. Giovanni Torsello, who presented the data at the 2014 Charing Cross international symposium in London, said in prepared remarks. "The long-term data reinforce the clinical leadership of the Endurant stent graft in an all-comer patient population."

The Engage data, presented at Charing Cross by Dr. Hence Verhagen, concerned a sub-set of patients with aneurysms of a certain "neck length" – or the span of healthy aortic tissue between the aneurysm and the lowest renal artery, according to the release.

Patients with neck lengths of 10mm to 15mm and 15mm or greater showed " similarly strong outcomes," Medtronic said. Analysis of 48 patients with shorter neck lengths, 79 with medium neck length and 364 patients with long neck lengths showed "no statistically significant differences" across the 3 groups, the company said. That included rates of aneurysm rupture, conversion to open surgery, secondary endovascular procedures and stent graft migration, Fridley, Minn.-based Medtronic said.

"The Endurant stent graft has opened up standard [endovascular aortic repair] to patients who were previously considered ineligible, and the Engage results support the usage of this device in patients with short necks (10mm and up)," Verhagen said in a statement. "The data also show that the Endurant stent graft successfully broadens patient eligibility for standard EVAR."

 

Filed Under: News Well, Stent Grafts Tagged With: Clinical Trials

More recent news

  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Endogenex data supports type 2 diabetes procedure
  • Ambu wins FDA clearance for first single-use cysto-nephroscope
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy